Avidity Biosciences

Researchers at University of Basel and Roche used CRISPR/Cas9 screening to identify genes that significantly influence antisense oligonucleotide (ASO) activity, revealing that intracellular transport speed is a critical determinant of therapeutic efficacy.

Applied DNA Sciences implemented a 27% workforce reduction and ceased operations at Applied DNA Clinical Labs to focus exclusively on its synthetic DNA manufacturing subsidiary LineaRx.

Sensible Biotechnologies has reduced mRNA optimization cycles from 15 days to just one day using NVIDIA-powered AI technology, representing a more than 90% time reduction.

Mirvie's blood test successfully identified 91% of preterm preeclampsia cases in women over 35 without pre-existing conditions, using RNA signatures detectable at 17.5-22 weeks gestation.

Cofactor Genomics' OncoPrism platform demonstrates 300-400% improvement in predicting patient responses to cancer immunotherapies compared to other clinical tests using AI and RNA expression data.

N4 Pharma has formed a new Senior Leadership Team comprising four experienced consultants with over 25 years each in drug development, manufacturing, and commercialization to advance its Nuvec® gene delivery platform.

Scientists at the University of Nottingham have developed a cryogenic mass spectrometry approach that reveals the precise structure and molecular orientation within lipid nanoparticles used in RNA therapeutics.

Biostate AI has raised $12 million in Series A funding led by Accel to develop affordable RNA sequencing technology and AI-powered diagnostic models.

Oligo Factory has launched a new low-scale oligonucleotide synthesis capability, enabling researchers to order custom DNA and RNA oligos in volumes as small as 50 nmol while maintaining high quality standards.

Eascra Biotech has received a $100,000 Stage I SBIR Targeted Technologies grant to advance their Janus Base Nanoparticles (JBNps) delivery platform for hard-to-reach tissues.